Third Quarter 2024 Net Revenues of $2.9 Million, Gross Profit of $2.2 Million and Gross Margin of 75% 2024 Net Revenue of $19.9 Million Through the 9 Months ended September 30, 2024 Represents a 61% Increase over FY 2023 Net Revenue of $12.3 Million New Pro-U.S. Border Security Administration Provides Additional Macro Tailwinds for 2025 […]
WESTLAKE VILLAGE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2024 and provided general business updates. The Company initiated its second lung cancer trial, a US-based, Phase 2 trial (VIRO-25) treating patients with recurrent advanced or metastatic non-small
Highlights Q3 2024 gross revenue increased 16% to $10.5 million compared to $9.1 million in Q3 2023 Q3 recurring revenue increased 14% to $5.5 million compared to $4.8 million Rekor Discover(TM) now on the Florida DOT Approved Product List, and deployments commenced Our CEO, David Desharnais, was inducted into the ITS America Board COLUMBIA, Md.,
Jiangyin, China, Nov. 14, 2024 (GLOBE NEWSWIRE) — Li Bang International Corporation Inc. (Nasdaq: LBGJ) (the “Company” or “Li Bang”), a company engaged in designing, developing, producing, and selling stainless steel commercial kitchen equipment in China, today announced the underwriters of its initial public offering (the “Offering”) have exercised their over-allotment option in full to
BETHESDA, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended September 30, 2024, and provides a corporate update. “The third quarter of
MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the third quarter ended September 30, 2024. “We have generated considerable momentum
Dallas TX, Nov. 14, 2024 (GLOBE NEWSWIRE) — Residents in Dallas and surrounding communities facing family violence charges can turn to the law office of John M. Helms, an established Dallas violence defense lawyer known for providing an exceptional level of representation and expertise in domestic violence defense cases. A Super Lawyer, specializing in defending
(NASDAQ:XPON), Q3 Sequential Revenue Growth of 8.7% Driven by New Products and Technologies Seven New OEM and Distributor Relationships to Equip New Campers and RVs with Advanced Lithium-Ion Batteries Closed $10 Million Underwritten Public Offering to Advance Commercialization of Home Energy Storage Solutions and Pursue Key Growth Initiatives REDMOND, Ore., Nov. 14, 2024 (GLOBE NEWSWIRE)
(NASDAQ:LSAK),(Johannesburg:LSK.JO), JOHANNESBURG, Nov. 14, 2024 (GLOBE NEWSWIRE) — Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) (“Lesaka” or the “Company”) shareholders voted on and approved the funding and issuance of shares to the Lesaka ESOP Trust at its annual general meeting. Lincoln Mali, CEO Southern Africa, said “We are very proud of the launch of our
(NASDAQ:ALMS), SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced the company will give two data presentations at ACR Convergence 2024, the